ITGA6: A Potential Drug Target Or Biomarker for Various Diseases

Target Name: ITGA6

NCBI ID: G3655

ITGA6

ITGA6: A Potential Drug Target Or Biomarker for Various Diseases

ITGA6 (Integrin alpha chain, alpha 6) is a protein that is expressed in various tissues throughout the body. It is a member of the integrin alpha chain, which is a subfamily of the transmembrane protein superfamily. Integrins are important for cell-cell adhesion and for the formation of tight junctions between epithelial cells. They are involved in many physiological processes, including embryonic development, tissue repair, and cancer progression.

Recent studies have identified ITGA6 as a potential drug target or biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In this article, we will review the current literature on ITGA6 and its potential as a drug target or biomarker.

Drug Target Potential

ITGA6 has been identified as a potential drug target for a variety of diseases due to its involvement in cell-cell adhesion and the formation of tight junctions.

1. Cancer

Studies have shown that ITGA6 is expressed in various types of cancer, including breast, ovarian, and prostate cancers. ITGA6 has been shown to promote the growth and survival of cancer cells, and it has been identified as a potential therapeutic target for cancer treatment.

2. Neurodegenerative Diseases

ITGA6 has been shown to be involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Studies have shown that ITGA6 levels are elevated in the brains of individuals with neurodegenerative diseases, and that inhibition of ITGA6 has been shown to protect against the progression of these diseases.

3. Autoimmune Disorders

ITGA6 has also been shown to be involved in the development and progression of autoimmune disorders, including rheumatoid arthritis and multiple sclerosis. Studies have shown that ITGA6 levels are elevated in individuals with autoimmune disorders, and that inhibition of ITGA6 has been shown to reduce the activity of immune cells and improve symptoms in these disorders.

Biomarker Potential

ITGA6 has also been identified as a potential biomarker for a variety of diseases.

1. Cancer

Studies have shown that ITGA6 has been used as a biomarker for cancer diagnosis and treatment. For example, researchers have shown that ITGA6 levels are elevated in various types of cancer, and that inhibition of ITGA6 has been shown to reduce the growth and survival of cancer cells.

2. Neurodegenerative Diseases

ITGA6 has also been used as a biomarker for neurodegenerative diseases. Studies have shown that ITGA6 levels are elevated in the brains of individuals with neurodegenerative diseases, and that inhibition of ITGA6 has been shown to protect against the progression of these diseases.

3. Autoimmune Disorders

ITGA6 has also been used as a biomarker for autoimmune disorders. Studies have shown that ITGA6 levels are elevated in individuals with autoimmune disorders, and that inhibition of ITGA6 has been shown to reduce the activity of immune cells and improve symptoms in these disorders.

Conclusion

In conclusion, ITGA6 is a protein that is expressed in various tissues throughout the body and has been shown to be involved in a variety of physiological processes, including cell-cell adhesion and the formation of tight junctions. Recent studies have identified ITGA6 as a potential drug target or biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to fully understand the role of ITGA6 in these diseases and to develop effective treatments.

Protein Name: Integrin Subunit Alpha 6

Functions: Integrin alpha-6/beta-1 (ITGA6:ITGB1) is a receptor for laminin on platelets (By similarity). Integrin alpha-6/beta-1 (ITGA6:ITGB1) is present in oocytes and is involved in sperm-egg fusion (By similarity). Integrin alpha-6/beta-4 (ITGA6:ITGB4) is a receptor for laminin in epithelial cells and it plays a critical structural role in the hemidesmosome (By similarity). ITGA6:ITGB4 binds to NRG1 (via EGF domain) and this binding is essential for NRG1-ERBB signaling (PubMed:20682778). ITGA6:ITGB4 binds to IGF1 and this binding is essential for IGF1 signaling (PubMed:22351760). ITGA6:ITGB4 binds to IGF2 and this binding is essential for IGF2 signaling (PubMed:28873464)

The "ITGA6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ITGA6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets